Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Lilly identifies new JAK1 inhibitors

Feb. 6, 2018

Fibrocell Science submits IND for gene therapy candidate for scleroderma

Feb. 6, 2018

Asahi Kasei launches Kevzara in Japan

Feb. 5, 2018

Anika Therapeutics collaborates with University of Liverpool on MSC therapy for osteoarthritis

Feb. 2, 2018

Pfizer enrolling patients in phase II study of PF-06823859 in moderate to severe dermatomyositis

Feb. 2, 2018

AstraZeneca initiates phase IIa study of AZD-9567 in rheumatoid arthritis

Feb. 1, 2018

European Commission grants approval to Taltz for active psoriatic arthritis

Jan. 25, 2018

The University of Kentucky patents prostaglandin E synthase inhibitors

Jan. 22, 2018

Etanercept biosimilar approved in Japan

Jan. 22, 2018

FDA accepts Sandoz's BLA for adalimumab biosimilar

Jan. 16, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...